To include your compound in the COVID-19 Resource Center, submit it here.

Japan approvals include Hemlibra, Shingrix, Galafold

Japan approved a basket of drugs including hemophilia drug Hemlibra emicizumab from Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), shingles vaccine Shingrix from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and Fabry's disease drug Galafold migalastat from Amicus Therapeutics Inc. (NASDAQ:FOLD).

Japan's Ministry of Health, Labour and Welfare (MHLW) approved Hemlibra to prevent or reduce the

Read the full 507 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE